ClinicalTrials.gg
RecruitingNCT07950722Updated Nov 20, 2026

A Novel Augmented Reality System (ARssist & ARport) for the Assistant Surgeon in Robotic Assisted Surgery:

An interventional study of ARssist and ARport system in Prostate Cancer, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 37 studies in Prostatic Neoplasms by Chinese University of Hong Kong — 15 open to participants now, 17 under way, none of them phase 3. Prostatic Neoplasms · Chinese University of Hong Kong.

Planned enrollment
14th of 20
30 · median 71
Started
2026
with 2 others
No phase
18 of 37
8 open now
Primary completion
2029-06
later than 13 of 16 live
Registered
37th of 37
by date

Among the 37 studies in Prostatic Neoplasms by Chinese University of Hong Kong, this one is the 14th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2026, is one of 18 with no phase, reaches primary completion later than 13 of the 16 other live ones, and was the 37th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 37 studies in Prostatic Neoplasms by Chinese University of Hong Kong are open now, in 2 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Prostatic Neoplasms by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

Robotic prostatectomy is a surgery for treating localized prostate cancer. The ARssist \& ARport system is a novel augmented reality system designed for the assistant surgeon, allowing delivery of augmented reality information. This study aims at evaluating the safety and feasibility of the use of ARssist \& ARport system in robotic prostatectomy.

Read the detailed description

This is a prospective study to evaluate the clinical feasibility and safety of the ARssist and ARport system during robotic surgery with Robotic surgical System. During the operation, the assistant surgeon will utilize the ARssist \& ARport system to assist the chief surgeon. Subjects will receive standard post-operative care. The primary objective of this study is to demonstrate the safety and clinical feasibility of the ARssist and ARport system in helping the patient side surgeon perform laparoscopic tasks during robotic assisted urological surgeries, with primary endpoints being safety data and complications.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Patient Inclusion Criteria

  1. Age >18 years
  2. \<35kg/m2
  3. Suitable for minimally invasive surgery
  4. Willingness to participate as demonstrated by giving
  5. Clinically diagnosed with urological conditions that are indicated for robotic assisted radical prostatectomy with or without lymph node dissection

Patient Exclusion Criteria

  1. to general anaesthesia
  2. Severe concomitant illness that drastically shortens or increases risk of therapeutic intervention
  3. Untreated active infection
  4. Uncorrectable coagulopathy
  5. Presence of another or distant
  6. Emergency surgery
  7. Vulnerable population (e.g. mentally incapacitated persons)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    ARssist & ARport System

    Device: ARssist and ARport system

Interventions

  • DeviceARssist and ARport system

    The surgery will follow the same steps of a standard robotic assisted radical prostatectomy procedure, with the addition of the ARssist and/or ARport system used by the patient side surgeon.

06

What researchers measure

Primary outcomes

  1. Number of intervention-related surgical complication

    All post-operative complications within 30 days. Complications will be classified based on the Clavien-Dindo classification of surgical complications

    Time frame: On Day 30

Secondary outcomes

  1. Performance of the patient side surgeon

    By Global Operative Assessment of Laparoscopic Skills( GOALS) checklist, a 5-item global rating scale scored on a 5-point scale, the higher mark reflect the better performance

    Time frame: Perioperative

  2. Specific feedback on the use of the system by patient side surgeon

    A customized questionnaire of 10 items on a 5-point Likert scale ; the items included are selected and adopted from the feedback questionnaire designed for a study on HoloLens use in ureteroscopic procedure; by a System Usability Scale; the NASA Task Load Index and the Simulator sickness questionnaire. The higher the marks reflect the better performance

    Time frame: Perioperative

  3. Operative Time

    The duration of operation

    Time frame: Perioperative

  4. Blood Loss

    The total amount of blood loss in the operation in ml

    Time frame: Perioperative

  5. Hospital Stay

    Duration of hospital stay in days

    Time frame: Perioperative

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Sgarbura O, Vasilescu C. The decisive role of the patient-side surgeon in robotic surgery. Surg Endosc. 2010 Dec;24(12):3149-55. doi: 10.1007/s00464-010-1108-9. Epub 2010 May 22. PubMed 20495980 ↗
  • Al Janabi HF, Aydin A, Palaneer S, Macchione N, Al-Jabir A, Khan MS, Dasgupta P, Ahmed K. Effectiveness of the HoloLens mixed-reality headset in minimally invasive surgery: a simulation-based feasibility study. Surg Endosc. 2020 Mar;34(3):1143-1149. doi: 10.1007/s00464-019-06862-3. Epub 2019 Jun 18. PubMed 31214807 ↗
  • Qian L, Deguet A, Kazanzides P. ARssist: augmented reality on a head-mounted display for the first assistant in robotic surgery. Healthc Technol Lett. 2018 Sep 17;5(5):194-200. doi: 10.1049/htl.2018.5065. eCollection 2018 Oct. PubMed 30800322 ↗
  • McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, Nicholl J; Balliol Collaboration; Aronson JK, Barkun JS, Blazeby JM, Boutron IC, Campbell WB, Clavien PA, Cook JA, Ergina PL, Feldman LS, Flum DR, Maddern GJ, Nicholl J, Reeves BC, Seiler CM, Strasberg SM, Meakins JL, Ashby D, Black N, Bunker J, Burton M, Campbell M, Chalkidou K, Chalmers I, de Leval M, Deeks J, Ergina PL, Grant A, Gray M, Greenhalgh R, Jenicek M, Kehoe S, Lilford R, Littlejohns P, Loke Y, Madhock R, McPherson K, Meakins J, Rothwell P, Summerskill B, Taggart D, Tekkis P, Thompson M, Treasure T, Trohler U, Vandenbroucke J. No surgical innovation without evaluation: the IDEAL recommendations. Lancet. 2009 Sep 26;374(9695):1105-12. doi: 10.1016/S0140-6736(09)61116-8. PubMed 19782876 ↗
  • Barkun JS, Aronson JK, Feldman LS, Maddern GJ, Strasberg SM; Balliol Collaboration; Altman DG, Barkun JS, Blazeby JM, Boutron IC, Campbell WB, Clavien PA, Cook JA, Ergina PL, Flum DR, Glasziou P, Marshall JC, McCulloch P, Nicholl J, Reeves BC, Seiler CM, Meakins JL, Ashby D, Black N, Bunker J, Burton M, Campbell M, Chalkidou K, Chalmers I, de Leval M, Deeks J, Grant A, Gray M, Greenhalgh R, Jenicek M, Kehoe S, Lilford R, Littlejohns P, Loke Y, Madhock R, McPherson K, Rothwell P, Summerskill B, Taggart D, Tekkis P, Thompson M, Treasure T, Trohler U, Vandenbroucke J. Evaluation and stages of surgical innovations. Lancet. 2009 Sep 26;374(9695):1089-96. doi: 10.1016/S0140-6736(09)61083-7. PubMed 19782874 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Jun 2029, 31 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 31 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2026
First posted
Nov 20, 2026
StartActual
Nov 1, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950722
Responsible party
Jeremy Yuen Chun TEOH (Associate Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Nov 20, 2026
Start date
Nov 1, 2026
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Yuen Chun Jeremy TEOH, MD
Contact
jeremyteoh@surgery.cuhk.edu.hk
35053933
Ho Ming Chiris WONG, MBChB
Contact
Yuen Chun Jeremy TEOH, MD
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion